<DOC>
	<DOCNO>NCT02797184</DOCNO>
	<brief_summary>The purpose study work necessary sufficient set appropriate multi-center , randomize clinical trial ( RCT ) new therapy heart failure : inorganic nitrate . The investigator first determine effect palatability ~12.8mmol KNO3 ( oral pill ) compare roughly equivalent amount nitrate 2 beetroot juice ( BRJ ) Sports Shots ( James White Drinks ) . Next , investigator determine effect inorganic nitrate ( KNO3 oral pill format ) blood pressure , blood nitrate level , breath nitric oxide ( NO ) level , exercise performance dose-response study . Third , investigator perform small phase II chronic treatment study allow determine best primary endpoint number patient investigator need study large , multi-center RCT follow project . In small study RCT follow , investigator determine whether inorganic nitrate improve aerobic exercise capacity , muscle power , speed muscle contraction , lessen effort breathe exercise .</brief_summary>
	<brief_title>Inorganic NItrate EXercise Performance Heart Failure ( iNIX-HF )</brief_title>
	<detailed_description>For substudies : A ) All Subjects consent . B ) All Subjects give permission investigator review medical record . C ) For study , Subjects patient HF . I . For beetroot juice ( BRJ ) vs. KNO3 study : 1 . After consent participate , subject instruct refrain spitting use antibacterial mouthwash , antacid , proton pump inhibitor , chew gum study . 2 . Subjects ask answer questionnaire regard medical health ( basic health questionnaire , Minnesota live heart failure questionnaire , combine fatigue questionnaire . 2a ) Subjects ask undergo physical examination . 3 ) Subjects interview dietician regard typical dietary intake instruct low nitrate diet . 4 ) In study visit # 1 subject randomize receive either two `` shot '' BRJ ( James White Drinks ) KNO3 capsule form , provide 12.8 mmol NO3- . 5 ) Before 3 time point receive BRJ placebo , subject undergo phlebotomy plasma nutrient/hormone level blood pressure check blow tube connect small machine measure amount nitric oxide breath . 6 ) Subjects undergo transthoracic echocardiographic image rest . 7 ) Subjects ask complete palatability questionnaire . 8 ) Subjects ask undergo mouth swab bacterial DNA analysis . 9 ) Subjects undergo 7 washout period . 10 ) Subjects come study day 2 receive whichever treatment ( BRJ KNO3 ) receive first repeat study list 1 ) , 5 ) 7 ) . II . For KNO3 dose-response study : 1 . After consent participate , subject instruct refrain spitting use antibacterial mouthwash , antacid , proton pump inhibitor , chew gum study . 2 . Subjects ask answer questionnaire regard medical health ( basic health questionnaire , Minnesota live heart failure questionnaire , combine fatigue questionnaire ) . 2a ) Subjects ask undergo physical examination . 3 ) Subjects interview dietitian regard typical dietary intake instruct low nitrate diet . 4 ) Subjects undergo transthoracic echocardiographic image rest . 5 ) In study visit # 1 subject randomize receive either 0 , 10 , 20 mmol NO3- form KNO3 . 6 ) Before 3 time point receive KNO3 , subject undergo phlebotomy plasma NO3- NO2- level blood pressure check blow tube connect small machine measure amount NO breath . 7 ) ~2 h ingestion , subject undergo 6 min walk test short physical performance battery test ; 8 ) Then subject swish , swallow ~ 4 TBSP dilute solution 10 mg-N/L nitrate . After 5 min subject spit container measurement . 9 ) Subjects undergo test neuromuscular function use isokinetic dynamometer ( device measure voluntary muscle force production control speed movement ) device measure grip strength . 10 ) Subjects perform cycle ergometer test determine VO2peak . Subjects blood pressure , heart rate rhythm monitor study . 11 ) Subjects ask undergo mouth swab bacterial DNA analysis . 12 ) Subjects undergo 7 washout period . 13 ) Subjects come study day 2 receive whichever treatment ( 0 , 10 , 20 mmol NO3- ) receive first repeat study list : 1 ) , 2 ) , 3 ) , 6 ) , 7 ) , 9 ) , 10 ) . 14 ) Subjects undergo 7 washout period . 15 ) Subjects come study day 3 receive whichever treatment ( 0 , 10 , 20 mmol NO3- ) receive first second study day repeat study list : 1 ) , 2 ) , 3 ) , 5 ) , 6 ) , 7 ) , 9 ) , 10 ) . III . For chronic KNO3 study : 1 . Subjects randomize receive either placebo KNO3 . 2 . Subjects ask undergo step 1-11 ) list dose response study ingest either KNO3 placebo , ingest KNO3 placebo least 2 week , undergo step 1 ) , 2 ) , 3 ) , 6 ) , 7 ) , 8 ) , 9 ) . The exercise study do ~ 2 h ingestion KNO3 day .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>1 . Age &gt; 18y &lt; 75y ; 2 . Diagnosis heart failure reduce ejection fraction ( NYHA IIIV ) ; 3 . Ejection fraction &lt; 45 % determine image study within 12 mo enrollment ; 4 . Stable medical therapy define addition removal ( change 100 % ) following : betaadrenergic blockade angiotensin convert enzyme ( ACE ) inhibitor angiotensin receptor blocker ( ARB aldosterone antagonists ) ) 30 day 1 . `` Vulnerable population '' define U.S. Department Health Human Services , include prisoner child exclude study . 2 . Pharmacologic , organic nitrate therapy within last 3 mo 3 . Major orthopedic , psychiatric , neurological , condition would impair performance study exercise outcomes 4 . Atrial fibrillation/flutter 5 . Estimated glomerular filtration rate &lt; 50ml/min recent clinical laboratory 6 . Systolic blood pressure &lt; 95mmHg &gt; 180mmHg consent 7 . Diastolic blood pressure &lt; 40mmHg &gt; 100mmHg consent 8 . Previous adverse reaction nitrate necessitate withdrawal therapy 9 . Treatment phosphodiesterase inhibitor within last 3 mo ( patient must also willing take duration trial ) . 10 . Ejection fraction &gt; 45 % 11 . Primary hypertrophic cardiomyopathy 12 . Infiltrative cardiomyopathy ( e.g. , amyloid ) 13 . Active myocarditis 14 . Complex congenital heart disease 15 . Active collagen vascular disease 16 . Percutaneous coronary intervention , new biventricular pacing , coronary artery bypass graft past 3 mo 17 . More mild mitral aortic stenosis 18 . Valvular heart disease severe regurgitation valve . 19 . Acute chronic severe liver disease evidence encephalopathy , INR &gt; 1.7 without anticoagulation therapy , variceal bleed 20 . Terminal disease ( heart failure ) expect survival &lt; 1 21 . Enrollment another therapeutic trial period study 22 . Pregnant woman 23 . Subjects require exogenous oxygen rest exercise exclude . 24 . Subjects active angina/ischemia epicardial coronary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>